10 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 10 separate news trends connected to Psilocybin, spanning June 21, 2026 through November 3, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 73 article observations and 69 source signals, led by Health, Business coverage. Use it to compare how individual events emerged, spread and changed over time.
Usona's NDA filing for psilocybin depression therapy intensifies a high‑stakes FDA race with Compass Pathways.
6 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Psilocybin, the active compound in 'magic mushrooms', may protect against nerve damage from chemotherapy.
A massive study of psilocybin's effects on the brain has revealed how context shapes the psychedelic experience
Oregon's psilocybin program shows promise in improving mental health, according to a real-world study
A major randomized clinical trial indicates that psilocybin, the active compound in magic mushrooms, provides relief for treatment-resistant depression.
6 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.
An 80-year-old woman with Alzheimer's has regained speech and mobility after taking psilocybin.
A controversial case report on psilocybin's effects on an Alzheimer's patient has sparked global interest.